143 related articles for article (PubMed ID: 37844433)
1. A paradigm shift for cardiovascular outcome evaluation in diabetes: Major adverse cardiovascular events (MACE) to major adverse vascular events (MAVE).
Rastogi A; Sudhayakumar A; Schaper NC; Jude EB
Diabetes Metab Syndr; 2023 Nov; 17(11):102875. PubMed ID: 37844433
[TBL] [Abstract][Full Text] [Related]
2. Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?
Marx N; McGuire DK; Perkovic V; Woerle HJ; Broedl UC; von Eynatten M; George JT; Rosenstock J
Diabetes Care; 2017 Sep; 40(9):1144-1151. PubMed ID: 28830955
[TBL] [Abstract][Full Text] [Related]
3. Incidence of Hospitalization for Heart Failure Relative to Major Atherosclerotic Events in Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials.
Sacre JW; Magliano DJ; Shaw JE
Diabetes Care; 2020 Oct; 43(10):2614-2623. PubMed ID: 32958618
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
Lin DS; Lee JK; Hung CS; Chen WJ
Diabetologia; 2021 Dec; 64(12):2676-2686. PubMed ID: 34536085
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
Ferdinand KC; Botros FT; Atisso CM; Sager PT
Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
[TBL] [Abstract][Full Text] [Related]
6. Shift from surrogate end point to outcome trials: implications for cardiovascular safety assessment in development programs for antidiabetic drugs.
Marcinak JF; Viswanathan P; Arora V; Roebel LE; Strack TR; Leifke E
Clin Pharmacol Ther; 2012 Mar; 91(3):514-20. PubMed ID: 22113235
[TBL] [Abstract][Full Text] [Related]
7. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study.
Mohammedi K; Woodward M; Hirakawa Y; Zoungas S; Colagiuri S; Hamet P; Harrap S; Poulter N; Matthews DR; Marre M; Chalmers J;
Cardiovasc Diabetol; 2016 Sep; 15(1):129. PubMed ID: 27590190
[TBL] [Abstract][Full Text] [Related]
8. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58.
Bonaca MP; Wiviott SD; Zelniker TA; Mosenzon O; Bhatt DL; Leiter LA; McGuire DK; Goodrich EL; De Mendonca Furtado RH; Wilding JPH; Cahn A; Gause-Nilsson IAM; Johanson P; Fredriksson M; Johansson PA; Langkilde AM; Raz I; Sabatine MS
Circulation; 2020 Aug; 142(8):734-747. PubMed ID: 32795086
[TBL] [Abstract][Full Text] [Related]
9. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.
Nicholls SJ; Bhatt DL; Buse JB; Prato SD; Kahn SE; Lincoff AM; McGuire DK; Nauck MA; Nissen SE; Sattar N; Zinman B; Zoungas S; Basile J; Bartee A; Miller D; Nishiyama H; Pavo I; Weerakkody G; Wiese RJ; D'Alessio D;
Am Heart J; 2024 Jan; 267():1-11. PubMed ID: 37758044
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial.
Badjatiya A; Merrill P; Buse JB; Goodman SG; Katona B; Iqbal N; Pagidipati NJ; Sattar N; Holman RR; Hernandez AF; Mentz RJ; Patel MR; Jones WS
Circ Cardiovasc Interv; 2019 Dec; 12(12):e008018. PubMed ID: 31752517
[TBL] [Abstract][Full Text] [Related]
11. Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits.
Hupfeld C; Mudaliar S
Diabetes Obes Metab; 2019 Aug; 21(8):1780-1789. PubMed ID: 30957945
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.
Lin DS; Yu AL; Lo HY; Lien CW; Lee JK; Chiang FT; Tu YK
Eur J Endocrinol; 2023 Jul; 189(1):S17-S25. PubMed ID: 37474112
[TBL] [Abstract][Full Text] [Related]
13. Restricted Mean Survival Time Analysis to Estimate SGLT2i-Associated Heterogeneous Treatment Effects on Primary and Secondary Prevention of Cardiorenal Outcomes in Patients With Type 2 Diabetes in Taiwan.
Peng ZY; Yang CT; Kuo S; Wu CH; Lin WH; Ou HT
JAMA Netw Open; 2022 Dec; 5(12):e2246928. PubMed ID: 36520437
[TBL] [Abstract][Full Text] [Related]
14. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial.
McGuire DK; Busui RP; Deanfield J; Inzucchi SE; Mann JFE; Marx N; Mulvagh SL; Poulter N; Engelmann MDM; Hovingh GK; Ripa MS; Gislum M; Brown-Frandsen K; Buse JB
Diabetes Obes Metab; 2023 Jul; 25(7):1932-1941. PubMed ID: 36945734
[TBL] [Abstract][Full Text] [Related]
15. SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2017 Apr; 10(4):429-442. PubMed ID: 28121469
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
Li CX; Liang S; Gao L; Liu H
PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.
Verma S; Al-Omran M; Leiter LA; Mazer CD; Rasmussen S; Saevereid HA; Sejersten Ripa M; Bonaca MP
Diabetes Obes Metab; 2022 Jul; 24(7):1288-1299. PubMed ID: 35332654
[TBL] [Abstract][Full Text] [Related]
18. Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial.
Verma S; Bain SC; Buse JB; Idorn T; Rasmussen S; Ørsted DD; Nauck MA
JAMA Cardiol; 2019 Dec; 4(12):1214-1220. PubMed ID: 31721979
[TBL] [Abstract][Full Text] [Related]
19. Sortilin levels correlate with major cardiovascular events of diabetic patients with peripheral artery disease following revascularization: a prospective study.
Biscetti F; Nardella E; Rando MM; Cecchini AL; Bonadia N; Bruno P; Angelini F; Di Stasi C; Contegiacomo A; Santoliquido A; Pitocco D; Landolfi R; Flex A
Cardiovasc Diabetol; 2020 Sep; 19(1):147. PubMed ID: 32977814
[TBL] [Abstract][Full Text] [Related]
20. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease.
Bonaca MP; Bhatt DL; Storey RF; Steg PG; Cohen M; Kuder J; Goodrich E; Nicolau JC; Parkhomenko A; López-Sendón J; Dellborg M; Dalby A; Špinar J; Aylward P; Corbalán R; Abola MTB; Jensen EC; Held P; Braunwald E; Sabatine MS
J Am Coll Cardiol; 2016 Jun; 67(23):2719-2728. PubMed ID: 27046162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
